Cogent Biosciences
COGT
180 hedge funds and large institutions have $973M invested in Cogent Biosciences in 2025 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 79 increasing their positions, 36 reducing their positions, and 35 closing their positions.
214% more call options, than puts
Call options by funds: $20.5M | Put options by funds: $6.52M
119% more repeat investments, than reductions
Existing positions increased: 79 | Existing positions reduced: 36
22% more capital invested
Capital invested by funds: $800M → $973M (+$174M)
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
1.79% more ownership
Funds ownership: 117.25% → 119.04% (+1.8%)
3% less funds holding
Funds holding: 186 → 180 (-6)
14% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$15.8M |
| 2 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
+$8.01M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$7.7M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$5.74M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$4.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$36.5M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$9.8M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$7.95M |
| 4 |
SG Americas Securities
New York
|
-$5.68M |
| 5 |
VA
VR Adviser
New York
|
-$5.15M |
COGT Hedge Fund Activity: Q2 2025 in Review
180 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q2 2025, worth a combined $973M — up 22% from $800M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of COGT and 30 opened new positions — a net loss of 5 holders — while 36 trimmed existing stakes and 79 added.
The largest buyer was Janus Henderson Group, adding an estimated $15.8M. The largest seller was Commodore Capital, cutting an estimated $36.5M.
- 180 institutional investors held Cogent Biosciences (COGT) as of Q2 2025, down from 186 in Q1 2025.
- Funds reported $973M of Cogent Biosciences stock for Q2 2025, up 22% quarter-over-quarter.
- 30 funds opened new Cogent Biosciences positions in Q2 2025 and 35 closed out, a net change of -5 holders.
- The largest Cogent Biosciences buyer in Q2 2025 was Janus Henderson Group, an estimated $15.8M added.
- The largest Cogent Biosciences seller in Q2 2025 was Commodore Capital, an estimated $36.5M sold.
Based on aggregated 13F filings for Q2 2025.